title: Benign, borderline, and malignant endometrioid neoplasia arising in endometriosis in association with tamoxifen therapy.
abstract: Tamoxifen therapy may result in a variety of endometrial proliferative lesions, including adenocarcinoma, and as recently suggested, proliferative changes within endometriosis. This report describes an endometrioid adenocarcinoma arising in ovarian endometriosis in a patient taking tamoxifen. There were also foci of benign and borderline endometrioid adenofibroma in the same ovary and a synchronous endometrioid endometrial adenocarcinoma in the uterus. The spectrum of benign, borderline, and malignant endometrioid neoplasia arising within endometriosis suggests that tamoxifen, as a result of its estrogenic effects, may cause proliferative and, in rare instances, malignant changes in endometriosis.
authors.affiliation: Department of Pathology, Royal Group of Hospitals Trust, Belfast, Northern Ireland.
authors.forename: W G
authors.initials: WG
authors.lastname: McCluggage
authors.forename: C
authors.initials: C
authors.lastname: Bryson
authors.forename: H
authors.initials: H
authors.lastname: Lamki
authors.forename: D D
authors.initials: DD
authors.lastname: Boyle
mesh_terms: D000230:Adenocarcinoma / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D001943:Breast Neoplasms / Q000188:drug therapy; D018269:Carcinoma, Endometrioid / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D016889:Endometrial Neoplasms / Q000139:chemically induced* / Q000473:pathology; D004715:Endometriosis / Q000473:pathology*; D004965:Estrogen Antagonists / Q000009:adverse effects; D005187:Fallopian Tubes / Q000601:surgery; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D010052:Ovariectomy; D013629:Tamoxifen / Q000009:adverse effects*
chemical_list: D004965:Estrogen Antagonists; D013629:Tamoxifen